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Abstract
Several studies in mouse model of invasive aspergillosis (IA) and in healthy donors have shown that different Aspergillus
antigens may stimulate different adaptive immune responses. However, the occurrence of Aspergillus-specific T cells have
not yet been reported in patients with the disease. In patients with IA, we have investigated during the infection: a) whether
and how specific T-cell responses to different Aspergillus antigens occur and develop; b) which antigens elicit the highest
frequencies of protective immune responses and, c) whether such protective T cells could be expanded ex-vivo. Forty
hematologic patients have been studied, including 22 patients with IA and 18 controls. Specific T cells producing IL-10, IFN-
c, IL-4 and IL-17A have been characterized through enzyme linked immunospot and cytokine secretion assays on 88
peripheral blood (PB) samples, by using the following recombinant antigens: GEL1p, CRF1p, PEP1p, SOD1p, a1–3glucan, b1–
3glucan, galactomannan. Specific T cells were expanded through short term culture. Aspergillus-specific T cells producing
non-protective interleukin-10 (IL-10) and protective interferon-gamma (IFN-c) have been detected to all the antigens only in
IA patients. Lower numbers of specific T cells producing IL-4 and IL-17A have also been shown. Protective T cells targeted
predominantly Aspergillus cell wall antigens, tended to increase during the IA course and to be associated with a better
clinical outcome. Aspergillus-specific T cells could be successfully generated from the PB of 8 out of 8 patients with IA and
included cytotoxic subsets able to lyse Aspergillus hyphae. Aspergillus specific T-cell responses contribute to the clearance of
the pathogen in immunosuppressed patients with IA and Aspergillus cell wall antigens are those mainly targeted by
protective immune responses. Cytotoxic specific T cells can be expanded from immunosuppressed patients even during the
infection by using the above mentioned antigens. These findings may be exploited for immunotherapeutic purposes in
patients with IA.
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Introduction
In mouse model of invasive aspergillosis (IA), previous studies
have reported that adaptive immunity contribute to the defence of
the host against fungi of the genus Aspergillus and that Aspergillus-
specific T cells producing interferon-gamma (IFN-c) may result
protective, while those producing interleukin-10 (IL-10) may result
non-protective to the fungus [1–3]. In healthy subjects, it has
subsequently been demonstrated that T cells may proliferate and
produce different amount of IL-10, IFN-c, IL-4 and IL-17A in
response to Aspergillus recombinant antigens and that the protective
T cells may be expanded from their peripheral blood as possible
source of adoptive therapy [4,5].
However, the emergence and changes of dynamics of Aspergillus-
specific T cells have not yet been described in patients with IA and
the above mentioned results could be barely applicable to
immunosuppressed patients during the common clinical practice.
Thus, we have phenotypically and functionally characterized
Aspergillus-specific T-cell responses against seven different Aspergillus
recombinant antigens either in patients with IA, during the course
of the infection, or in a comparable number of controls, and
identified which antigens are most frequently targeted by
protective immune responses. The results in patients with IA
and controls have been compared with those obtained in healthy
subjects (HS). Furthermore, Aspergillus-specific T cells have been
expanded from the peripheral blood of patients with IA.
Materials and Methods
Ethics Statement
Written informed consent was obtained according to the
Declaration of Helsinki, and after the local Ethical Committee’s
study approval (Comitato Etico Provinciale di Modena – protocol
nu 2414–63/11).
Patients
Forty hematologic patients were studied: 22 patients with IA, 16
proven and 6 probable cases according to the current diagnostic
criteria [6], and 18 patients with infectious complications other
than IA or without infections (Table 1). Furthermore to validate
the results in IA and control patients we have also studied the
occurrence of specific immune response in 13 HS.
ELISpot for the Detection of Aspergillus-specific T Cells
The enzyme linked immunospot (ELISpot) assay has been
performed to detect Aspergillus-specific T cell producing IL-10,
IFN-c, IL-4 and IL-17A, on 101 peripheral blood samples, by
using seven recombinant antigens of Aspergillus. Peripheral blood
mononuclear cells (PBMCs) were obtained by Ficoll-Hypaque
gradient centrifugation and co-cultured for 18–40 hours on a 96-
well bottom plates coated with anti-cytokine antibodies, namely
anti-IL10, anti-IFN-c, anti-IL4 and anti-IL17A, as previously
reported [7,8]. The viability of the analysed T cells has been
determined by stimulation with anti-CD3 antibody. Aspergillus-
specific T cells producing IL-10, IFN-c, IL-4 were evaluated in 13
out of 13 HS; while those producing IL-17A in 4 out of 13 HS.
Based on our previous studies, a sample was considered positive
if all the followings were fulfilled: 1) the presence of at least 10 spot
forming cells (SFCs); 2) the presence of more than 10 SFCs in the
sample compared with the negative control; 3) the presence of a
stimulation index of $20 (defined as the ratio of the number of
SFCs in the positive control to that in the negative control) [7–9].
The 7 different recombinant antigens of Aspergillus were used at
a concentration of 5–7 mg/mL, and included: 1) two glycosylpho-
sphatidylinositol (GPI)-anchored proteins namely 1,3-b glucano-
syltransferase (GEL1p) and an ortholog of Crh1p associated in
b1,6 glucan-chitin linkages (CRF1p) in Saccharomyces cerevisiae; 2)
two secreted proteins, such as the aspartic protease (PEP1p) and
superoxide dismutase (SOD1p); 3) three major polysaccharides of
the cell wall such as a1–3 glucan, b1–3 glucan, and galactoman-
nan. All the antigens have been produced, purified and harnessed
as previously reported [5,10,11].
ELISpot results have been reported as median spot forming cells
(SFCs)/10‘6 PBMCs with their 25th and 75th percentile values.
Cytofluorimetric and Functional Characterization of
Aspergillus-specific T cell
In patients with IA, on peripheral blood samples resulted
positive at the ELISpot assay, we have phenotypically and
functionally characterized Aspergillus-specific T cells to the seven
recombinant antigens by using the cytokine secretion assay (CSA)
for IFN-c, IL-10, IL-4, IL-17A, according to the manufacturer’s
instructions (CSA Detection Kit; Miltenyi Biotec), as already
reported [7,8], with few modifications. Briefly, 16106 PBMCs
were stimulated with Aspergillus recombinant antigens, at a final
concentrations of 5–7 mg/mL, from 17 to 40 hours, according to
the cytokine studied. After stimulation, PBMCs were immuno-
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stained with IFN-c, IL-10, IL-4, or IL-17 catch reagent, and the
phenotype of the cytokine producing T cells was directly assessed
after sample counterstaining, as reported [7,8]. Unstimulated and
PHA-stimulated PBMCs were used as negative and positive
controls, respectively. Cells were acquired on a FACSCalibur flow
cytometer (BD Biosciences) and analyzed by the use of CellQuest
(BD Biosciences) and Summit softwares (Dako). Frequencies of
antigen-reactive effector memory (EM) or central memory (CM) T
cells were calculated as mean differences compared with
unstimulated controls. CD8+ or CD4+ T cells were gated on
CD3+ events after passing through a small lymphocyte gate. The
phenotype of the cytokine producing cells was directly assessed
after sample counterstaining with CD3 APC, CD8 FITC or
PerCP, CD4 PerCP or APC, CD62L or CCR7 PE, allowing the
identification of EM T cells (CD3+, CD8+ or CD4+, CD62L2/
CCR72) or CM T cells (CD3+, CD8+ or CD4+, CD62L+/
CCR7+). Results were expressed as mean percentages of either PB
CD8+ T cells or CD4+ T cells 6 standard deviation (SD).
Aspergillus-specific T cells Expansion and Demonstration
of Lytic Activity
Aspergillus-specific T cells were obtained by culturing PBMCs
from 8 patients with IA: 1) alone, as control; 2) with a mixture of
Aspergillus recombinant antigens (PEP1p, GEL1p, a1–3 glucan and
b1–3 glucan) (8 ug/mL); and 3) with heat killed germinated
conidia (100.000/ml), for 13 days in the presence of IL-2, IL-7
and IL-5. To further functionally characterize Aspergillus-specific T
cells, we investigated the presence of specific-cytotoxic T cell
subsets by means of the colorimetric assay with (2,3-bis[2-
methoxy-4-nitro-5-sulfophenyl]2H-tetrazolium-5-carboxyanilide)
sodium salt (XTT; Sigma) plus coenzyme Q0 (2,3-dimethoxy-5-
methyl-1,4-benzoquinone; Sigma). Before the assessment of their
lytic activity, cells from short term cultures were phenotypically
characterized. An Aspergillus fumigatus isolate from one of the
patients has been used as target. T-cell induced specific hyphal
damage has been assessed as follows. Briefly, conidia of Aspergillus
fumigatus (1.56104 per well) were plated in a 96-well flat bottom
plate and incubated at 37uC for 16 hours to allow germination.
On the following day, unstimulated and stimulated anti-Aspergillus
T cells were added at an effector-to-target (E/T) ratio of 3:1 and
5:1 and incubated at 37uC with 5% CO2 for 2 and 22 hours,
respectively, and each experimental condition was performed in
triplicate. Anti-hyphal activity was expressed as a specific hyphal
damage and was calculated according to the formula: percent
hyphal damage = [12((X2Y)/C)] 6100, where X is the absor-
bance of experimental wells with stimulated cells, Y is the
absorbance of experimental wells with unstimulated cells and C is
the absorbance of control wells with hyphae only. In three out of 8
patients, to evaluate whether anti-hyphal activity of Aspergillus-
specific T cells was similar to those of antigen presenting cells
(APCs) and polymorphonuclears (PMNs) and how it was
accomplished, we compared the killing ability of anti-Aspergillus
T cells, APCs, PMNs and the supernatant of T-cell cultures.
Furthermore, we quantified the amount of cytokines (Granzyme B
and IFN-c) produced by PBMCs after 24 h culture with the above
mentioned antigens by enzyme linked immunosorbent assay
(ELISA).
Phases of Invasive Aspergillosis
Based on the kinetics of radiologic signs of pulmonary IA on
HRCT [12,13], the infection course has been divided into four
phases, defined from t1 to t4, and corresponding to the number of
days elapsed from the radiological diagnosis of IA (t1, from the
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from day +15 until day +30; t3, from day +31 to day +45; t4, from
day +46 to day 60 days from the radiological diagnosis of IA).
Only two patients had a sample collected more than 61 days after
the radiological demonstration of IA and the respective results
were shown as t4+.
Statistical Analysis
The Fischer’s exact test has been used to determine if there were
nonrandom associations between two categorical variables and the
outcome of the patients; the association between the number of
antigens targeted by specific T cells and the status of the subjects
(HS or patients with IA). Chi-squared test has been used to
compare the rate of samples with more than 100 SFCs/10‘6
PBMCs to all the antigens between HS and patients with IA. The
paired T test has been used to compare the rates of fungal hyphae
lysis between the single cell fractions and their associations. P
values below.05 were considered significant. The results were
obtained using the Stata Software (11.0, College Station, Texas,
USA).
Results
Identification of Aspergillus-specific T cells
A median of 2 time-points were analysed for each patient (range
from 1 to 5) (Table 1). All the patients with IA presented Aspergillus-
specific T cells at least at one time point (Figures 1 and 2).
Specific T cells (median SFCs/10‘6 PBMCs with their 25th and
75th percentile values) producing IL-10 were detected to all the
antigens: CRF1p 375 (130–550); PEP1p 160 (45–375); GEL1p
175 (75–400); a1–3glucan 150 (20–300); b1–3glucan 110 (30–
240); SOD1p 198 (60–510); Galactomannan 40 (30–45). The
frequencies of specific T cells producing IL-10 to all the antigens
increased in the first three phases [125 (42.5–360) at t1; 175 (60–
330) at t2; 375 (60–580) at t3] and tended to decrease in the fourth
phase of the infection [97.5 (30–480) at t4] (Figure 3 A,B).
Specific T cells producing IFN-c (median SFCs/10‘6 PBMCs
with their 25th and 75th percentile values) were also detected to all
the antigens: CRF1p 40 (20–80); PEP1p 30 (10–70); GEL1p 70
(35–100); a1–3glucan 55 (25–80); b1–3glucan 65 (25–80); SOD1p
35 (15–60); Galactomannan 17.5 (10–27.5). The frequencies of
specific T cells producing IFN-c to all the antigens remained stable
in the first three phases (40 (25–75) at t1; 35 (20–85) at t2; 30
(12.5–60) at t3) and increased after 45 days of IA [60 (25–80) at t4]
(Figure 3 C,D).
Patients who never showed specific T cells producing IFN-c or
demonstrated such cells against only one antigen (pts 16, 17, 18,
19, 20, 21, 22), presented more frequently an unfavourable
outcome compared with patients presenting protective immune
responses versus two or more antigens. Actually, 4 (pts 17, 19, 21,
22) out of 7 patients died of IA in the first group, while only 1 (pt
nu1) out of 15 patients died of the infection in the second group
(p = 0.021) (Figures 1 and 2).
Specific T cells producing IL-4 and IL-17A could be detected in
only one patient (pt7; Figure 1) by the ELISpot assay.
In the 18 control patients the occurrence of Aspergillus-specific T
cells could not be demonstrated (Table 1).
Figures 1. Kinetics of specific T-cell responses to the seven recombinant antigens of Aspergillus by IFN-c, IL-10, and IL-4 ELISpot
assay in 22 patients with invasive aspergillosis (IA), patient 1 to patient 10.
doi:10.1371/journal.pone.0074326.g001
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In the HS, specific T cells (median SFCs/10‘6 PBMCs with
their 25th and 75th percentile values) producing IL-10 were
detected to CRF1p 55 (20–90) in 11 out of 13; GEL1p 12.5 (10–
15) in 2 out of 13; a1–3glucan 10 (10–10) in 1 out of 13; b1–
3glucan 10 (10–15) in 6 out of 13; SOD1p 20 (10–35) in 3 out of
13; Galactomannan 10 (10–15) in 1 out of 13. No HS
demonstrated specific T cells producing IL-10 to PEP1p
(Figure 4 A).
Specific T cells (median SFCs/10‘6 PBMCs with their 25th and
75th percentile values) producing IFN-c were detected to CRF1p
690 (209–1285) in 10 out of 13; GEL1p 10 (10–10) in 1 out of 13;
SOD1p 10 (10–10) in 1 out of 13; Galactomannan 14 (14–14) in 1
out of 13 (Figure 4 B).
Specific T cells (median SFCs/10‘6 PBMCs with their 25th and
75th percentile values) producing IL-4 were detected to CRF1p 16
(10–16) in 3 out of 13 and to Galactomannan 16 (16–16) in 1 out
of 13 (Figure 4 C).
Specific T cells (median SFCs/10‘6 PBMCs with their 25th and
75th percentile values) producing IL-17A were detected to CRF1p
36 (14–120) in 3 out of 4; PEP1 37 (10–64) in 2 out of 4; GEL1p
30 (30–30) in 1 out of 4; a1–3glucan 64 (64–64) in 1 out of 4; b1–
3glucan 39 (30–48) in 2 out of 4; SOD1p 52 (46–58) in 2 out of 4;
Galactomannan 47 (32–62) in 2 out of 4 (Figure 4 D).
The comparison of specific immune responses producing IL-10
and IFN-c between patients with IA and HS demonstrated that: 1)
patients with IA presented higher number of Aspergillus-specific T
cells producing IL-10 (100 or more SFCs/10‘6 PBMCs) to each of
the seven recombinant antigens than HS (55.56% vs 2.2% of the
tested samples, p = .0001); 2) patients with IA presented wider
antigenic specificity (directed to 4 or more antigens) of Aspergillus-
specific T cells producing either IL-10 (77.27% of the IA patients
Figure 2. Kinetics of specific T-cell responses to the seven recombinant antigens of Aspergillus by IFN-c, IL-10, and IL-4 ELISpot
assay in 22 patients with invasive aspergillosis (IA), patient 11 to patient 22. Blue columns represent the number of Aspergillus-specific T
cells producing IFN-c; yellow columns represent the number of Aspergillus-specific T cells producing IL-10; green columns represent the number of
Aspergillus-specific T cells producing IL-17A; red columns represent the number of Aspergillus-specific T cells producing IL-4; dark gray background
represents T-cell responses in wells with anti-CD3 antibody. Vertical axis shows the number of spot-forming cells (SFCs) per million peripheral blood
mononuclear cells (PBMCs); horizontal axis indicates the antigen, which the specific immune responses are directed to and the phase of IA calculated
as the number of days elapsed from the radiological diagnosis of the infection (t1, from the radiologic disclosure of the infectious lesions until day
+14; t2, from day +15 until day +30; t3, from day +31 to day +45; t4, from day +46 to day 60 days; t4+ .61 days). CRF1 = ortholog of Crh1p associated
in b1,6 glucan-chitin linkages; PEP1 = aspartic protease; GEL1 = 1,3-b glucanosyltransferase; a1–3 glu = a1–3 glucan; b1–3 glu = b1–3 glucan; SOD1 =
superoxide dismutase; and GM = galactomannan. Pt = patient. * = patients with unfavorable outcome. ‘ = patients with probable IA. The red dotted
line divides the two groups of patients: from pt nu 1 to pt nu 15 with Aspergillus-specific T cells producing IFN-c to two or more antigens; from pt nu
16 to pt nu 22 without Aspergillus-specific T cells producing IFN-c or with such cells to only one antigen.
doi:10.1371/journal.pone.0074326.g002
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vs 15.38% of HS, p = .0001) or IFN-c (54.25% of the IA patients vs
0% of HS, p = .031).
Phenotypic and Functional Characterization of
Aspergillus-specific T cells
The CSA analysis showed that antigen-specific T cells were: 1)
either CD8+ or CD4+ T cells producing IFN-c (mean 6 SD
CD8+/CD4+: 0.1960.13/0.1760.10%), the former either CM or
EM (0,1260.16/0.1760.12), the latter predominantly EM
(0.1560.11/0.0360.03); 2) predominantly CD4+ T cells produc-
ing IL-10 (mean CD8+/CD4+: 0.0560.05/0.1060.06%) of EM
phenotype; 3) predominantly CD8+ T cells producing IL-4
(median CD8+/CD4+: 0.7260.034/0.2260.30%) of EM pheno-
type (mean CD8+ EM/CM 0.5660.50/0.1160.15%); 4) either
CD8+ or CD4+ T cells producing IL-17A (mean CD8+/CD4+:
0.2060.11/0.1660.16%) both mainly of EM phenotype (CD8+
EM/CM = 0.1660.13/0.0960.07; CD4+ EM/CM = 0.126
0.16/0.0460.03) (Figure 5A,B).
Lytic Activity of Aspergillus-specific T cells
After the 13-day cultures, from five out of five patients with IA,
with the mixture of PEP1p, GEL1p, a1–3 glucan and b1–3
glucan, we were able to expand a mean of 95.8% CD3+ cells (95%
CI 94.7%–97.8%), either CD4+ or CD8+ (mean values 38.5%/
Figure 3. Aspergillus-specific T-cell responses to the 7 recombinant antigens during the course of Invasive Aspegillosis (IA). A,B,C,D.
A. Box plots showing specific immune responses producing IL-10 (yellow columns) to any single recombinant antigen. The horizontal axis represents
the antigen, which the specific immune responses are directed to. B. Box plot showing specific immune responses producing IL-10 (yellow columns)
against all the 7 recombinant antigens at the four phases of the IA. The horizontal axis represents the different phases of IA. C. Box plot showing
specific immune responses producing IFN-c (blue columns) to any single recombinant antigen. The horizontal axis represents the antigen, which the
specific immune responses are directed to. D. Box plot showing specific immune responses producing IFN-c (blue columns) against all the 7
recombinant antigens at the four phases of the IA. The horizontal axis represents the different phases of IA. The vertical axis shows the number of
spot-forming cells (SFCs) per million peripheral blood mononuclear cells (PBMCs).The upper horizontal line represents the upper adjacent value. The
upper hinge of the boxes represents the 75th percentile. The middle horizontal line of the boxes represents the median value. The lower hinge of the
boxes represents the 25th percentile. The lower horizontal line represents the lower adjacent value. Yellow dots and blue dots are outrange values.
doi:10.1371/journal.pone.0074326.g003
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56.2%, 95% CI, 29.3%–44.2% and 51.6%–66.5%, respectively),
of either CM or EM phenotype (mean 58.3%/78.6%, 95% CI,
44.2%–59.4% and 70.5%–79.2%, respectively). Specific hyphal
damage was demonstrated at either 3:1 or at 5:1 effector:target
cells ratios, at significant levels (mean +2SD 9.63% +2 3.54,
ranges from 5.12% to 12.95%, 95%CI, 6.83%–12.43%), compa-
rable to that observed with T cells expanded with germinated
conidia (9.45+23.17, ranges from 5.75% to 12.77%; 95%CI,
6.87%–12.6%; p..05) (Figure 5C). Moreover, specific T cells
obtained from three further patients at the same culture
conditions, at 5:1 effector:target cells ratio, demonstrated specific
hyphal damage comparable to that of either APCs or PMNs (mean
lytic rates +2SD, 95% CI: T cells expanded with the mixture of
antigens = 17.89+25.68, 3.78–31.99; APCs = 16.2+25.84, 1.69–
30.70; PMNs = 18.63+25.60, 4.72–32.54). Only the association of
all the cell fractions produced a statistical significant increase of
hyphal damage (mean lytic rates +2SD, 95% CI: T cells
expanded with the mixture of antigens+APCs+PMNs =
41.4+24.18, 2.14–9.75; p,.05). Of note, the lysis of Aspergillus
hyphae by using only the supernatant from anti-Aspergillus T-cell
lines was less than a half of that obtained by incubating hyphae
with the whole cytotoxic T-cell lines (CTLs) cultures (mean lytic
rates +2 SD, 95% CI: supernatant from CTLs expanded with the
mixture of antigens = 5.93+21.52, 2.14–9.714) (Figure 5D). The
ELISA quantification showed higher values of Granzyme B and
IFN-c in the 24 hour supernatants from the cultures either
stimulated with conidia or the mixture of antigens, when
compared with the supernatant from unstimulated controls.
Figure 4. Aspergillus-specific T-cell responses to the 7 recombinant antigens in 13 Healthy Subjects. A,B,C,D. A. Box plots showing
specific immune responses producing IFN-c (blue columns) to any single recombinant antigen. B. Box plot showing specific immune responses
producing IL-10 (yellow columns) to any single recombinant antigen C. Box plot showing specific immune responses producing IL-4 (red columns) to
any single recombinant antigen. D. Box plot showing specific immune responses producing IL-17A (green columns) to any single recombinant
antigen. The vertical axis shows the number of spot-forming cells (SFCs) per million peripheral blood mononuclear cells (PBMCs). The horizontal axis
represents the antigens, which the specific immune responses are directed to. The upper horizontal line represents the upper adjacent value. The
upper hinge of the boxes represents the 75th percentile. The middle horizontal line of the boxes represents the median value. The lower hinge of the
boxes represents the 25th percentile. The lower horizontal line represents the lower adjacent value. Dots are outrange values.
doi:10.1371/journal.pone.0074326.g004
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Figure 5. Cytokine production profile and lytic activities of Aspergillus-specific T cells. A, B. The frequencies of Aspergillus specific T cells
producing IFNc, IL-10, IL-4 or IL-17A against the seven recombinant antigens, either as EM (dark gray portion of the columns) or CM (light gray
portion of the columns), are shown as mean % positive cells 6 standard deviation, computed over the 22 patients with IA. Results are expressed as
percentages of either CD4+ T cells (A) or of CD8+ T cells (B). C. White columns represent rates of hyphal damage by Aspergillus-specific T cells
expanded from PBMCs stimulated with heat killed Aspergillus conidia. Black columns represent rates of hyphal damage by Aspergillus-specific T cells
expanded from PBMCs stimulated with Aspergillus recombinant antigens (GEL1, PEP1, a1–3 glucan, b1–3 glucan) at two and twenty two-hour
T Cells in Patients with Aspergillosis
PLOS ONE | www.plosone.org 9 September 2013 | Volume 8 | Issue 9 | e74326
Granzyme B (median cytokine value; range): in culture stimulated
with conidia: 145 pg/mL (113–173); in culture stimulated with the
mixture of antigens: 196 pg/mL (75–239); in unstimulated
control: 45 pg/mL (31–150). IFN-c (median cytokine value;
range): in culture stimulated with conidia: 93 pg/mL (11–527);
in culture stimulated with the mixture of antigens: 110 pg/mL (5–
707); in unstimulated control: 47 pg/mL (4–77).
Discussion
Here we report, for the first time, how Aspergillus-specific
immune responses to different Aspergillus antigens may emerge and
develop in patients with IA. The absence of such immune
responses in patients without IA demonstrates that: a) they are
specific to Aspergillus spp., b) unrelated to the administered
treatments, c) and not in antithesis with previous reports and
our data showing Aspergillus specific T cells in healthy subjects [4].
Indeed, intensive chemotherapy may cause the reduction of such
cells at frequencies below the ELISpot threshold, while the
occurrence of IA, with the antigen rechallenge, may increase again
specific immune responses. Moreover, compared with the results
obtained in HS, patients with IA demonstrated noticeably higher
frequencies of Aspergillus-specific T cells producing IL-10 and
Aspergillus-specific T cells producing IFN-c with wider antigenic
specificity, implying that, given such a set of antigens, the
occurrence of high number of the former cells and of a wide
antigenic specificity of the latter may represent the immunologic
signature of IA. These data may also provide the rationale for
further studies to use the ELISpot as a novel diagnostic tool for IA.
Of note, Aspergillus-specific T cells producing IL-17A may be
detected more frequently and to more antigens in HS than in
patients with IA, suggesting that the loss of such cells may be
implicated in the pathogenesis of IA. However, further data are
necessary to draw any firm conclusions about this.
Our study shows that although IA is predominantly character-
ized by the presence of specific T cells producing IL-10, protective
immune responses may occur since the onset of and tend to
increase during IA. The antigens eliciting the highest frequencies
of specific T cells producing IFN-c are all involved in cell wall
biosynthesis of Aspergillus, namely GEL1p and both glucans,
partially in agreement with the results obtained in mice with IA,
where GEL1p, CRF1p and a1–3 glucan resulted the antigens
associated with a higher activation of type 1 responses [5]. The
recognition of polysaccharides is probably mediated by specific T
cells through the class II major histocompatibility complex (MHC)
on APCs, as previously reported for other infectious agents
showing glycoantigens, such as Staphylococcus aureus, Streptococcus
pneumoniae and Bacteroides fragilis [14,15]. Moreover, in our patients,
the association between T cells producing IFN-c to two or more
antigens and a more favorable outcome may suggest that such
protective T cells play a role in the resolution of the infection.
The functional and phenotypical characterization shows that
Aspergillus-specific T cells are either CD4+ or CD8+ T cells, and
that T cells producing either IL-4 or IL-17A may be detected to all
the antigens, suggesting that they are present at very low
frequencies in patients with IA. These findings confirm that
CD8+ T cells contribute to the immune response to filamentous
fungi [7,16], and are in line with those reports showing that
Aspergillus fumigatus is a weak inducer of IL-4 and IL-17A responses
[5,17].
The absence of concordance between the Elispot assay and
CSA, in particular about the frequencies of specific T cells
producing IL-10, IL-4 and IL-17A is not unexpected and reflects
the different intrinsic characteristics of the two assays, being the
ELISpot assay more suitable to detect low-level responses and to
define such responses as either positive or negative, while the CSA
more appropriate for a phenotypic discrimination of responding
cells, as already reported [7,16–18].
By expanding previous findings, so far obtained only in healthy
donors [19–21], we have expanded Aspergillus-specific T cells from
PB of patients with IA using a mixture of recombinant antigens
different from CRF1p, and found that such cells may induce direct
lysis of Aspergillus hyphae, comparable to those obtained by APCs
and PMNs. By showing that the hyphal lysis obtained with the
supernatant of anti-Aspergillus CTLs is lower than that registered
with the whole CTLs culture (anti-Aspergillus CTLs+supernatant),
and that the production of Granzyme B and IFN-c was higher in
stimulated samples, our data suggest that the activity against
Aspergillus is mediated directly by T cells, either by secreting
cytokines or by cell-cell contact, and are consistent with previous
reports [22,23]. The observation that protective immune responses
in HS are almost exclusively elicited by CRF1p, while they are
predominantly directed to Aspergillus cell wall antigens in patients
with IA, should be taken into account when planning immuno-
therapeutic strategies.
In conclusion, specific immune responses to several Aspergillus
antigens may be detected in patients with IA and those producing
IFN-c directly mediate the lysis of Aspergillus hyphae, possibly
contributing to the clearance of the fungus, being their presence
also associated with a more favourable outcome. The identifica-
tion of the antigens eliciting the strongest protective responses in
patients with IA may spur further studies to define the complete
repertoire of Aspergillus specific immune responses during the
course of the infection to design therapeutic strategies of either
vaccine or autologous cytotoxic cell infusions.
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